What happened with STAA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
STAAR Surgical makes lenses that surgeons implant in the eye to correct vision without removing the natural lens or corneal tissue. These Implantable Collamer Lenses, or ICLs, use its proprietary Collamer material. Its EVO and EVO+ lenses account for nearly all sales. They offer patients an alternative to laser vision correction such as LASIK and SMILE.
Patients generally pay for this elective surgery themselves because insurance usually does not cover it. STAAR earns money by selling the lenses through its own sales representatives and independent distributors that supply hospitals. Most revenue comes from outside the United States, and two distributors serving China and Hong Kong account for a substantial share of sales. Their orders depend on both demand for surgery and the inventory they already hold, so hospital use and distributor purchases do not always move together.
The business depends heavily on patients’ willingness and ability to pay for surgery, particularly in China. Product availability also depends on local regulatory approvals: in the United States, EVO lenses are approved for myopia and myopia with astigmatism. New or modified products and manufacturing processes require regulatory review or approval, which limits what STAAR can sell and how it can change production.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
STAAR’s results depend heavily on Chinese demand for vision-correction surgery and distributor inventories; Carl Zeiss Meditec is another important laser-surgery rival to watch beyond this list.
Alcon sells lasers for corneal vision-correction surgery, competing for patients who could instead choose STAAR’s implantable lenses. Watch its refractive-laser business rather than overall sales, which also include other surgical products, contact lenses and eye-health products.
Bausch + Lomb’s vision-correction lasers compete with STAAR’s implantable lenses for patients choosing surgery. Its laser-business news is more relevant to STAAR than total revenue: Surgical accounted for just 18% of Bausch + Lomb’s 2025 revenue and also includes other eye-surgery products.
Johnson & Johnson sells corneal vision-correction lasers that compete with STAAR’s implantable lenses, but this is a small part of its diversified business. Watch laser-surgery news rather than prescription-medicine results, which reflect sales to retailers, wholesalers, distributors, hospitals and healthcare professionals.
Staar Surgical Co earningsThis company
STAAR Surgical’s report will show whether ICL sales can steady amid weak China demand while the company protects its manufacturing margin.
Read ICL sales alongside gross margin, the share of sales left after product costs. Steadier sales with a stable margin would suggest demand is improving without giving up unit economics. Weak sales or a falling margin would point to distributors still buying less, or lower production and inventory costs continuing to squeeze profit.
Alcon Inc. earningsALC
Alcon’s report will show how demand for its corneal refractive lasers is changing, offering a read on the competition for patients who might choose STAAR Surgical’s ICLs.
Focus on Alcon’s refractive-laser business, not total sales, which also include other surgical products, contact lenses and eye-health products. Growth in lasers would show that demand for this competing procedure remains firm, leaving STAAR Surgical under pressure to win refractive-correction patients. A slowdown would show that laser demand is softening, but would not prove patients are switching to ICLs.
